Ciclazindol

Pharmacokinetic dataMetabolismRenal^[1]Elimination half-life~32 hours^[1]ExcretionUrine, feces^[1]IdentifiersCAS NumberPubChem CIDChemSpiderUNIIKEGGChEMBLChemical and physical dataFormulaC₁₇H₁₅ClN₂OMolar mass298.77 g·mol⁻¹3D model (JSmol)

Ciclazindol (WY-23409) is an antidepressant and anorectic^[2] drug of the tetracyclic^{[citation needed]} chemical class that was developed in the mid to late 1970s, but was never marketed.^[3][4] It acts as a norepinephrine reuptake inhibitor, and to a lesser extent as a dopamine reuptake inhibitor.^[3][5] Ciclazindol has no effects on the SERT, 5-HT receptors, mACh receptors, or α-adrenergic receptors, and has only weak affinity for the H₁ receptor.^[5][6][7] As suggested by its local anesthetic properties,^[6] ciclazindol may also inhibit sodium channels. It is known to block potassium channels as well.^[8][9]

The dosage in human volunteers is stated to be 25mg daily.^[1] However, doses of up to 200mg have also been reported.^[2] This is surprising since the dosage of mazindol is only 2-4mg per day.

Ciclazindol is reported to have an IC50 of 1.3nM for the dopamine transporter (cmp 23).^[10]

See also

• Mazindol
• Setazindol

References